Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New DNA test aims to predict bloodstream infections in kids with cancer

NCT ID NCT03226158

Knowledge-focused Sponsor: St. Jude Children's Research Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jul 21, 2026 · Updated 3 times

Summary

This study at St. Jude Children's Research Hospital is testing whether a next-generation DNA test can predict bloodstream infections in children and teens with cancer who are at high risk. Current methods often detect infections too late, leading to severe illness or death. The goal is to see if this test can spot infection early, so doctors can give the right antibiotics sooner and reduce the use of broad-spectrum drugs that fuel antibiotic resistance. About 160 participants are being followed to measure how accurate the test is.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
next generation sequencing (DNA test) of pathogens
What this could lead to
If successful, this could lead to a way to predict bloodstream infections days before they become dangerous, allowing doctors to start targeted antibiotics earlier and avoid broad-spectrum drugs.
What could go wrong
This is an early-stage study focused on measuring how accurate the test is, not yet proving it improves outcomes. The test may not be sensitive or specific enough in real-world settings.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

160 people

The number who actually took part.

Started

Aug 2017

Expected to finish

Jul 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Participants who are being treated at St. Jude Children's Research Hospital and who have a high risk of infection.

Ages

Up to 24 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Under 25 years of age at time of study enrollment * Undergoing care for cancer at St. Jude * In a category of patients who are considered by the investigator to be at high risk of infection * Expected to receive care at St. Jude for at least 7 days Exclusion Criteria: * Any condition that would, in the opinion of the investigator, place the subject at an unacceptable risk of injury or render the subject unable to meet the requirements of the protocol.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Bloodstream infection are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

bacterial infectious disease with sepsis cancer neoplasm Sepsis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Bloodstream infection

Contacts and locations

Locations

  • St. Jude Children's Research Hospital

    Memphis, Tennessee, 38105, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.